Skip to main content
PMC home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1972 Nov 4;107(9):851–855.

Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide

Daniel E Bergsagel, Donald H Cowan, Richard Hasselback
PMCID: PMC1940819  PMID: 4653931

Abstract

High-dose intermittent cyclophosphamide was used in the treatment of 19 patients with plasma cell myeloma who had demonstrated resistance to melphalan. Good objective improvement was found in six patients and partial responses in five. Patients have survived from three to more than 36 months (estimated median 21 months) after starting cyclophosphamide, and 11 are still alive. The important implications of the lack of cross-resistance between these two alkylating agents are discussed in terms of the mechanisms of cellular resistance to alkylating agents.

Full text

PDF
851

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Bergsagel D. E., Migliore P. J., Vaughn W. K., Howe C. D. Melphalan therapy for plasma cell myeloma. Blood. 1968 Jan;31(1):1–10. [PubMed] [Google Scholar]
  2. Alexanian R., Haut A., Khan A. U., Lane M., McKelvey E. M., Migliore P. J., Stuckey W. J., Jr, Wilson H. E. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969 Jun 2;208(9):1680–1685. doi: 10.1001/jama.208.9.1680. [DOI] [PubMed] [Google Scholar]
  3. Bergsagel D. E., Griffith K. M., Haut A., Stuckey W. J., Jr The treatment of plasma cell myeloma. Adv Cancer Res. 1967;10:311–359. doi: 10.1016/s0065-230x(08)60081-0. [DOI] [PubMed] [Google Scholar]
  4. CALCUTT G., CONNORS T. A. TUMOUR SULPHYDRYL LEVELS AND SENSITIVITY TO THE NITROGEN MUSTARD MEROPHAN. Biochem Pharmacol. 1963 Aug;12:839–845. doi: 10.1016/0006-2952(63)90114-x. [DOI] [PubMed] [Google Scholar]
  5. CUTLER S. J., EDERER F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958 Dec;8(6):699–712. doi: 10.1016/0021-9681(58)90126-7. [DOI] [PubMed] [Google Scholar]
  6. Chun E. H., Gonzales L., Lewis F. S., Jones J., Rutman R. J. Differences in the in vivo alkylation and cross-linking of nitrogen mustard-sensitive and -resistant lines of Lettré-Ehrlich asites tumors. Cancer Res. 1969 Jun;29(6):1184–1194. [PubMed] [Google Scholar]
  7. Goldenberg G. J., Vanstone C. L., Bihler I. Transport of nitrogen mustard on the transport-carrier for choline in L5178Y lymphoblasts. Science. 1971 Jun 11;172(3988):1148–1149. doi: 10.1126/science.172.3988.1148. [DOI] [PubMed] [Google Scholar]
  8. Goldenberg G. J., Vanstone C. L., Israels L. G., Iise D., Bihler I. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts. Cancer Res. 1970 Sep;30(9):2285–2291. [PubMed] [Google Scholar]
  9. HIRONO I. Non-protein sulphydryl group in the original strain and sub-line of the ascites tumour resistant to alkylating reagents. Nature. 1960 Jun 25;186:1059–1060. doi: 10.1038/1861059a0. [DOI] [PubMed] [Google Scholar]
  10. Hoogstraten B., Sheehe P. R., Cuttner J., Cooper T., Kyle R. A., Oberfield R. A., Townsend S. R., Harley J. B., Hayes D. M., Costa G. Melphalan in multiple myeloma. Blood. 1967 Jul;30(1):74–83. [PubMed] [Google Scholar]
  11. KORST D. R., CLIFFORD G. O., FOWLER W. M., LOUIS J., WILL J., WILSON H. E. MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS. JAMA. 1964 Sep 7;189:758–762. [PubMed] [Google Scholar]
  12. McArthur J. R., Athens J. W., Wintrobe M. M., Cartwright G. E. Melphalan and myeloma. Experience with a low-dose continuous regimen. Ann Intern Med. 1970 May;72(5):665–670. doi: 10.7326/0003-4819-72-5-665. [DOI] [PubMed] [Google Scholar]
  13. Roberts J. J., Crathorn A. R., Brent T. P. Repair of alkylated DNA in mammalian cells. Nature. 1968 Jun 8;218(5145):970–972. doi: 10.1038/218970a0. [DOI] [PubMed] [Google Scholar]
  14. Rutman R. J., Chun E. H., Lewis F. S. Permeability difference as a source of resistance to alkylating agents in Ehrlich tumor cells. Biochem Biophys Res Commun. 1968 Aug 21;32(4):650–657. doi: 10.1016/0006-291x(68)90288-x. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES